Basic Parlodel Information

• INN (International Nonproprietary Name): Bromocriptine
• Brand Names Available In Canada (English): Parlodel (worldwide; tablets commonly 2.5 mg blister packs), Parlodel Sandoz (Europe, similar packaging), Bromocriptin-ratiopharm (EU generics), Cycloset (USA diabetes formulation)
• ATC Code: G02CB01 (Bromocriptine)
• Forms & Dosages: Tablets 2.5 mg commonly sold; 5 mg strength exists in some countries but is rare
• Manufacturers In Canada (English): not specified
• Registration Status In Canada (English): not specified
• OTC / Rx Classification: Rx only (prescription required in nearly all markets)

Key Findings From Recent Trials (2022–2025)

Major 2022–2025 Canadian & Global Studies

Patients and prescribers have asked whether older dopamine agonists still matter after 2021 trends toward cabergoline.

Large observational datasets from North America and Europe show declining first-line use of bromocriptine in favour of cabergoline because of better tolerability and less frequent dosing.

Randomised and real-world small studies in 2022–2025 revisited bromocriptine for metabolic endpoints such as insulin resistance and MAFLD, with mixed signals and limited replication.

Trials using the Cycloset formulation—bromocriptine for glycaemic control approved in the US—resurfaced in metabolic research settings during this period.

Main Outcomes

Comparative effectiveness work largely reinforced that cabergoline is preferred for prolactin control when tolerated and available.

Bromocriptine produced modest improvements in some metabolic markers in small trials, but results were inconsistent across studies.

Real-world Canadian hospital data show stable, targeted use of bromocriptine for niche indications and specialist‑led Parkinson’s regimens rather than broad primary‑care prescribing.

Safety Observations

Post‑market surveillance from 2022–2025 highlighted orthostatic hypotension and psychiatric events, particularly in elderly and Parkinson’s cohorts.

Regulators used post‑market reports to update risk‑minimisation advice in several jurisdictions during this timeframe.

Pharmacies continued to report Parlodel commonly sold in 2.5 mg tablets in blister packs under ATC G02CB01.

Clinical Mechanism Of Action

Layman’s Explanation

Patients often ask what Parlodel actually does in the body.

Bromocriptine is a dopamine D2 receptor agonist that lowers prolactin levels produced by the pituitary gland.

It also improves dopaminergic signalling in the brain to help motor symptoms in Parkinson’s disease.

Certain formulations can modestly lower blood glucose as part of metabolic treatment strategies.

Scientific Breakdown

Bromocriptine is an ergot derivative that binds centrally and at pituitary lactotrophs to inhibit prolactin secretion.

The drug can also suppress growth hormone secretion in some acromegaly patients and alter central autonomic outflow.

Receptor Pharmacology

The primary pharmacologic action is high‑affinity dopamine D2 receptor agonism.

At higher doses, partial activity at D1 receptors and interactions with serotonin receptors can contribute to variable central nervous system effects.

Systemic Effects

Prolactin suppression is the main therapeutic effect for hyperprolactinemia management.

Other systemic effects include possible growth hormone suppression in acromegaly, peripheral vasospasm in rare cases, and autonomic changes that can cause orthostatic hypotension.

From a pharmacokinetic perspective, standard tablet forms are 2.5 mg and have a shorter half‑life compared with cabergoline, so dosing is more frequent and this affects tolerability and adherence.

Clinical implication: frequency of dosing and side‑effect profile are major drivers of choice between bromocriptine and alternatives.

Scope Of Approved And Off‑Label Use

Health Canada Approvals (DIN‑Based)

Globally, bromocriptine is approved for hyperprolactinemia, Parkinson’s disease adjunctive therapy, and acromegaly.

The US FDA lists multiple indications and the Cycloset formulation is approved for type 2 diabetes in that jurisdiction.

Health Canada product registration details and DIN listings should be checked by prescribers and pharmacists for any marketed product; the RAW DATA does not specify current Canadian DIN registrations.

Notable Off‑Label Trends In Canadian Practice

In Canada between 2022 and 2025, specialist endocrinologists sometimes prescribe bromocriptine when cabergoline is contraindicated or unavailable.

Low‑dose regimens for insulin resistance and metabolic syndrome appear in research clinics, but these uses remain experimental and require specialist oversight.

Use of bromocriptine for postpartum lactation suppression is largely discouraged due to cardiovascular risk, and is rarely recommended in current practice.

Dosage Strategy

General Dosing Per Health Canada Monographs

Start low and go slow is the typical approach to minimise nausea and orthostatic symptoms.

Standard starting doses for adults with hyperprolactinemia are 1.25–2.5 mg once or twice daily with gradual titration.

Condition‑Specific Dosing Adjustments

Hyperprolactinemia: usual starting dose 1.25–2.5 mg qd or bid; maintenance up to 7.5 mg/day in divided doses; maximum recorded use up to 15 mg/day where indicated.

Acromegaly: start 1.25–2.5 mg qd/bid and titrate slowly; some patients require up to 20–30 mg/day under specialist supervision.

Parkinson’s disease: typical specialist regimens start 1.25 mg qd/bid and titrate; maintenance doses commonly range 10–40 mg/day with rare specialist cases exceeding this.

Cycloset (US diabetes formulation): start 0.8 mg qd and titrate to 1.6–4.8 mg qd over 2–4 weeks in US practice; Cycloset is not a standard Canadian diabetes product.

Titration And Monitoring

Increase dose slowly to reduce nausea and orthostatic hypotension.

Antiemetic prophylaxis or taking doses with food in the morning frequently helps early tolerability.

Baseline and follow‑up prolactin testing are standard when treating hyperprolactinemia, with dose adjustments guided by specialist advice.

Consider ECG monitoring in patients with cardiac history or when very high doses are used.

For elderly patients, begin at a lower dose and monitor closely for confusion, hallucinations, and falls related to hypotension.

Safety Protocols

Contraindications (Canadian Advisories)

Absolute contraindications include uncontrolled hypertension, current or past severe psychotic disorders, known hypersensitivity to bromocriptine or other ergot derivatives, and postpartum women with pre‑eclampsia/eclampsia or severe cardiovascular risk.

Pharmacists and prescribers should verify cardiovascular and psychiatric history before dispensing.

Adverse Effects (Post‑Market Reports)

Common adverse effects include nausea, headache, dizziness, fatigue, orthostatic hypotension, and constipation.

Less common but important effects are digital vasospasm and neuropsychiatric effects such as confusion or hallucinations, especially in older adults and Parkinson’s patients on higher doses.

Surveillance from 2022–2025 emphasised orthostatic events and psychiatric signals, which informed updated guidance in several regions.

Risk Mitigation Steps

Start at a low dose and titrate slowly while counselling patients on side effects and safety precautions.

Advise patients to rise slowly from sitting or lying positions and to avoid driving until they know how the medicine affects them.

Review concomitant medications that may lower blood pressure or prolong the QT interval, and counsel about alcohol which can increase sedation.

Report suspected adverse reactions to Health Canada’s Canada Vigilance Program as part of routine pharmacovigilance.

Interaction Mapping

Food Interactions Common In Canadian Diet

Taking bromocriptine with food reduces nausea and is practical for patients eating typical Canadian meals.

High‑fat meals may slightly alter absorption but do not generally prevent use; advising morning dosing with food is common.

Avoid excessive alcohol when starting therapy because sedation and dizziness risks increase.

Drug Combinations Flagged By Health Canada

Concurrent use with antihypertensives can produce additive hypotension and requires blood pressure monitoring.

Strong CYP3A4 inhibitors may raise bromocriptine levels, so monitor for increased adverse effects if combined.

Antipsychotics that antagonise D2 receptors will blunt effectiveness and can complicate psychiatric status.

Parkinson’s polypharmacy raises the risk of hallucinations when combining multiple dopamine agonists.

Practical Counselling Points

Check the patient’s current medication list at dispensing and flag interactions in pharmacy records including DIN and brand.

Advise patients to avoid driving or operating machinery until they know how they react to the medication.

Document prescriber details and any provincial prior authorisation requirements when submitting claims to provincial drug programs.

Patient Experience Analysis

Canadian Survey Data

Canadian patients report effective prolactin control in many cases but early adverse effects such as nausea and dizziness frequently drive discontinuation without supportive counselling.

Community surveys show that dosing frequency contributes to adherence challenges compared with once‑or‑twice‑weekly cabergoline regimens.

Forum & Community Pharmacy Trends

Online patient forums and pharmacy feedback in Canada between 2022 and 2025 discuss cost, access, and side effects as common themes.

Pharmacies report most prescriptions arrive via specialist referrals for acromegaly and Parkinson’s, while GPs often manage hyperprolactinemia prescriptions.

Practical pharmacy roles include supporting titration, providing antiemetic strategies, and assisting with prior authorisations for provincial plans such as ODB, BC PharmaCare, and RAMQ.

Distribution And Pricing Landscape

National Pharmacy Chains

Parlodel and generic bromocriptine 2.5 mg tablets are stocked across major chains, though local availability varies by province and store.

Typical Canadian retail outlets carrying prescription medicines include Shoppers, Rexall, Jean Coutu, and London Drugs.

Online Pharmacy Availability & Provincial Restrictions

Licensed Canadian online pharmacies may dispense parlodel with an e‑prescription and offer home delivery subject to Rx verification, bilingual labelling, and DIN checks.

Provincial drug plans have differing coverage rules and prior‑authorisation requirements for dopamine agonists and second‑line agents.

In our online pharmacy, parlodel is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Cross‑Border US Comparisons

Generic bromocriptine is generally cheaper than branded cabergoline in most markets, but price differences across the US‑Canada border depend on insurance coverage and specific formulations like Cycloset.

Always check DIN and packaging (Parlodel commonly in 2.5 mg blister packs) when comparing suppliers.

Alternative Options

Comparison Table Of DIN‑Approved Alternatives

Common alternatives to bromocriptine for hyperprolactinemia include cabergoline and quinagolide where available.

Cabergoline advantages are longer half‑life, less frequent dosing, and generally better tolerability compared with bromocriptine.

Quinagolide is an alternative in some markets with once‑daily dosing for hyperprolactinemia but has limited availability in Canada.

Pros And Cons Checklist

• Cabergoline: Pros — longer half‑life, easier dosing, better tolerability; Cons — valvulopathy signal at very high cumulative doses requiring monitoring.
• Quinagolide: Pros — once‑daily dosing for some patients; Cons — limited availability in Canada.
• Pergolide: Pros — older dopamine agonist historically used in Parkinson’s; Cons — withdrawn or restricted in many countries and not widely recommended.

Decision factors include indication, pregnancy plans, cardiovascular history, liver/renal function, cost, and provincial formulary coverage.

Regulatory Status

Health Canada Approval Process

Health Canada requires a Notice of Compliance and a Drug Identification Number (DIN) for each marketed formulation of an active substance; each product is evaluated for safety, efficacy, and quality.

Specific CN product listings for bromocriptine should be confirmed in Health Canada databases and provincial formularies, as the RAW DATA does not list Canadian DINs.

DIN And Bilingual Labelling Rules

Canadian packaging rules require bilingual English/French labelling and a visible DIN on outer packaging, which pharmacists must check at dispensing.

Adverse events should be reported to Canada Vigilance to support ongoing pharmacovigilance and potential product‑monograph updates.

Consolidated FAQ

Q1: Is Parlodel available in Canada and do I need a prescription?

A1: Yes — Parlodel (bromocriptine) formulations are Rx only in nearly all markets; pharmacies verify DIN and prescriber details at dispensing.

Q2: How quickly does it lower prolactin and what monitoring is needed?

A2: Prolactin often falls within weeks; baseline and follow‑up prolactin checks are standard, and dose adjustments are guided by an endocrinologist.

Q3: Can I drive when starting treatment?

A3: Avoid driving until you know how the medicine affects you because dizziness and orthostatic hypotension are common early effects.

Q4: Is it covered by provincial drug plans?

A4: Coverage varies across programs like ODB, BC PharmaCare, and RAMQ; prior authorisation may be required, so check provincial formularies and DIN listings.

Q5: Is cabergoline preferred?

A5: Many specialists prefer cabergoline for tolerability and dosing convenience, but bromocriptine remains a useful option where appropriate or when cabergoline is not suitable.

Visual Guide (Infographic Content Notes)

Dosage Flowchart Notes:

Start 1.25–2.5 mg once daily → Reassess nausea/blood pressure in 3–7 days → Titrate by 1.25 mg increments every 1–2 weeks to effective dose → Monitoring checkpoints: baseline and periodic prolactin, blood pressure, and mental status.

Provincial Coverage Map Notes:

Show icons for ODB, BC PharmaCare, and RAMQ with prior‑authorisation cues; indicate that provincial rules vary and DIN verification is required.

Purchase Channels Infographic Notes:

In‑store chains: Shoppers, Rexall, Jean Coutu, London Drugs.

Online pharmacy checklist: valid prescription, DIN verification, bilingual labelling, secure shipping.

Design Items To Include:

Parlodel 2.5 mg blister image, ATC G02CB01 text, Rx symbol, contraindication quick‑card listing uncontrolled hypertension, psychosis, and ergot hypersensitivity.

Accessibility: include bilingual leaflet suggestions and pharmacist contact details for each province.

Storage And Transport

Canadian Household Guidelines

Store bromocriptine tablets at room temperature away from excess moisture and heat and keep in original blister packaging until use.

Avoid storing medication in bathrooms or other humid locations; a pantry or bedroom medicine box is preferable.

Label medication with DIN and expiry and keep out of reach of children.

Cold‑Chain Storage Where Applicable

Bromocriptine tablets do not require refrigeration and do not need cold‑chain handling for routine distribution.

Avoid prolonged exposure to extreme cold during winter travel or to heat such as a vehicle dashboard during summer.

Licensed pharmacies should package shipments securely with bilingual labelling and consider temperature protection in extreme weather.

Guidelines For Proper Use

Advice From Canadian Pharmacists

Confirm the indication, review contraindications and interactions, and counsel on titration to reduce early adverse effects.

Provide clear instructions to take with food and to stand up slowly to reduce orthostatic dizziness.

Advise patients about missed doses (take when remembered unless near next dose; do not double) and when to seek urgent care for severe symptoms such as chest pain or severe confusion.

Provincial Health Authority Guidance

Follow provincial formularies for reimbursement and prior authorisation rules and consult specialists for high‑dose regimens in acromegaly and Parkinson’s disease.

Practical Dispensing Checklist

• Verify prescriber identity and indication and check DIN on the product packaging.
• Screen for absolute contraindications: uncontrolled hypertension, psychotic disorders, ergot allergy, postpartum pre‑eclampsia risks.
• Discuss common side effects and safety steps: nausea management, orthostasis precautions, avoiding driving until stable.
• Document lot number, DIN, dispensed quantity, and counselling provided in patient record.
• Report adverse events to Canada Vigilance and liaise with the prescriber about monitoring plans.

Delivery Across Canada (English)

Final Notes For Patients And Pharmacists

Parlodel is an established dopamine D2 agonist with clear indications and a known safety profile that requires careful patient selection and monitoring.

Pharmacists should prioritise screening for cardiovascular and psychiatric contraindications and support patients through early titration to improve adherence.

When cost, dosing frequency, or tolerability are important, consider cabergoline or other alternatives while consulting specialist guidance.

Always check the DIN, ensure bilingual labelling, and report adverse events to Canada Vigilance.

For patients seeking access, licensed Canadian pharmacies and major chains stock bromocriptine 2.5 mg tablets in blister packs and can assist with prescriptions and provincial coverage questions.